Young people are increasingly using Wegovy and Ozempic, study finds

Public interest in weight loss drugs like Wegovy and Ozempic is surging, but national data on dispensing patterns in the United States is surprisingly scarce.

Now, a national study from Michigan Medicine shows that the use of these weight loss drugs is increasing rapidly in adolescents and young adults aged 12–25 years, especially females.

Using 2020–2023 data from a national database representing 92% of pharmacies, the study team found a 594% increase in the monthly number of adolescents and young adults using Wegovy, Ozempic, and other glucagon-like peptide-1 receptor agonists (GLP-1RAs).

For females, this increase was even more pronounced. The number of female adolescents 12-17 years using GLP-1RAs increased 588%, compared with 504% for male adolescents. The number of female young adults 18-25 years using GLP-1 RAs increased 659%, compared with 481% for male young adults.

“This is the first study to document national trends in GLP-1RA dispensing in any population, including youth, said Joyce Lee, MD, MPH, the lead author of the paper. Lee is a pediatric endocrinologist and Professor of Pediatrics in the Susan B. Meister Child Health Evaluation and Research Center at the University of Michigan Medical School, the C.S. Mott Children’s Hospital, and the Caswell Diabetes Institute.

GLP-1RAs were approved for type 2 diabetes in 2005 and for weight management in 2014.

Interest in these drugs surged in 2021 when semaglutide was approved for weight management in adults under the brand name Wegovy, and increased even further when Wegovy was approved for weight management in adolescents at the end of 2022.

The report finds that endocrinologists, family medicine physicians and nurse practitioners were among the top prescribers of GLP-1 RAs to youth, suggesting that these clinicians should be the focus of efforts to ensure safe and appropriate prescribing.

For example, because the biggest usage increase occurred in females, clinicians need to educate female patients about the potential safety risks of these GLP-1 RAs during pregnancy.

The report also found that dispensing of Ozempic increased in youth, even though Ozempic is not approved in children for type 2 diabetes or weight management.

“This finding suggests increasing off-label use of Ozempic for weight management in adolescents and young adults,” said Kao-Ping Chua, MD, the senior author of the paper and a member of the CHEAR Center.

Lee adds that some concerns have been raised about both the cost of GLP-1 RAs, which are expensive and meant to be taken over the long term, as well as the unknown effects of these drugs on growth and development in youth.

“The increasing use of GLP-1 RAs highlights the importance of understanding the long-term safety, efficacy, and cost-effectiveness of GLP-1RAs in adolescents and young adults,” she said.

Additional authors include Lauren Oshman, M.D., M.P.H., Dina H. Griauzde, M.D., MS.c.